View full meeting coverage »

Eyetube Meeting Coverage:

OIS RETINA 2018

 

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

GenSight Biologics

  Channels: Retina | Posted 7/23/2018

Barrett Katz, MD, Chief Medical Officer, GenSight Biologics, provides updates on its two gene therapy programs, GS010, which is in phase 3 trials for Leber hereditary optic neuropathy, and GS030 for retinitis pigmentosa.


1 / 11 Series: OIS RETINA 2018